Overview

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective: - To assess the activity of lenalidomide in patients with previously untreated chronic lymphocytic leukemia (CLL) age 65 and older. Secondary Objective: - To assess the tolerability of lenalidomide in patients with untreated CLL age 65 and older
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Celgene
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide